株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

抗体・薬物複合体 (ADC) の世界市場:薬物別分析 (ADCETRIS, Kadcyla)、パイプライン分析 (相別、作用機序別、リンカー別、技術別、症状別)、将来展望

Global Antibody Drug Conjugates Market By Drug (ADCETRIS, Kadcyla), Pipeline Analysis (By Phase, Mode of Action, Linker, Technology, and Indication) Outlook 2022

発行 RNCOS E-Services Pvt. Ltd. 商品コード 297685
出版日 ページ情報 英文 120 Pages
即納可能
価格
本日の銀行送金レート: 1USD=113.24円で換算しております。
Back to Top
抗体・薬物複合体 (ADC) の世界市場:薬物別分析 (ADCETRIS, Kadcyla)、パイプライン分析 (相別、作用機序別、リンカー別、技術別、症状別)、将来展望 Global Antibody Drug Conjugates Market By Drug (ADCETRIS, Kadcyla), Pipeline Analysis (By Phase, Mode of Action, Linker, Technology, and Indication) Outlook 2022
出版日: 2017年02月13日 ページ情報: 英文 120 Pages
概要

当レポートでは、世界の抗体・薬物複合体(以下ADC)市場について分析し、全体的な産業構造や、上市済み製品の市場動向、治験中の主要薬剤の概要と今後の開発見通し、近年の市場・企業動向、主な産業促進・阻害要因、主要企業のプロファイルなどを調査しています。

第1章 アナリストの見解

第2章 分析手法

第3章 抗体・薬物複合体 (ADC):概略

第4章 ADC市場の将来展望

  • ADCETRIS
    • 市場の将来性
    • 市場規模とその予測(今後6年間分)
  • Kadcyla

第5章 ADCのパイプライン製品の分析

  • 企業別
    • 臨床段階別 (相別)
    • 薬物別
    • リンカーの種類別
    • 作用機序別
    • 技術別
  • 研究機関別
    • 相別
    • 症状別
    • 薬物別
    • リンカーの種類別
    • 作用機序別

第6章 市場促進・抑制要因

  • 促進要因
    • 世界各地でのがん患者の増加
    • リンク技術の進歩:ADC市場の再活性化
    • ADC市場促進のための、特許保護への努力
    • ADCの需要増大
  • 課題
    • 生産面での障害とコスト
    • 熟練したメーカーの不足
    • 規制面での課題

第7章 パイプライン上の主なADCの将来性

  • 企業別
  • 研究機関別

第8章 市場の傾向と動静

  • 血液悪性腫瘍の治療の最前線に立つADC
  • 乳がん患者に対するADCの効果

第9章 ADC業界における戦略的な事業提携

第10章 企業分析

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

Antibody Drug Conjugates are monoclonal antibodies that are attached to biologically active drugs by chemical linkers with labile bonds. They combine the unique targeting property of monoclonal antibodies with the cancer cell killing ability of cytotoxic drugs. These allow discrimination between healthy and diseased tissues. Advancements in coupling monoclonal antibodies to cytotoxic drugs permit better control of drug pharmacokinetics, and significantly improve delivery to target tissue. Potent novel anti-cancer drugs can now be used to target cancers, while minimizing the exposure of healthy tissue. The recent approvals of two potent ADCs - ADCETRIS and Kadcyla, followed by several Antibody Drug Conjugates (ADCs) in pipeline highlight the potential for new therapeutic innovations in this industry.

According to the RNCOS report entitled "Global Antibody Drug Conjugates Market By Drug (ADCETRIS, Kadcyla), Pipeline Analysis (By Phase, Mode of Action, Linker, Technology, and Indication) Outlook 2022", the ADC market is poised to reach US$ 18.1 Billion by 2022. In this report, there is in-depth market analysis of ADCETRIS and Kadcyla. The market potential of these ADCs is estimated considering that these are being tested in clinical trials for several cancer indications, besides the ones which have already been approved. The depicted ADCs are expected to show their complete market potential soon in the coming years.

Furthermore, in this report, we have structured the information regarding ADCs at various stages of clinical development that are under research or in collaboration, and those individually being developed by companies. The pipeline chapter provides in depth analysis of ADCs of companies as well as research organizations by clinical phase, indications for which they are being developed, mode of action, type of linker, drugs, and technology. Additionally, the study provides all-inclusive current analysis of various ADCs in advanced as well as early stages of development. Moreover, our report places an emphasis on the major drivers and challenges, latest trends and developments, as well as strategic collaborations that can impact industry's growth.

In the end, the report enlists some of the key players in the ADC market including in-short business overview of each player along with their product and pipeline portfolios, recent developments, and comparative analysis of their strengths and weaknesses. Conclusively, the report will prove to be a complete and comprehensive source of knowledge and analysis for clients and potential investors or debut makers in this industry.

Table of Contents

1. Analyst View

2. Research Methodology

3. Antibody Drug Conjugate (ADC) - An Introduction

4. ADC Market Outlook to 2022

  • 4.1 ADCETRIS
    • 4.1.1 Market Potential
    • 4.1.2 Market Size and Forecast to 2022
  • 4.2 Kadcyla
    • 4.2.1 Market Potential
    • 4.2.2 Market Size and Forecast to 2022

5. ADC Pipeline Analysis

  • 5.1 By Companies
    • 5.1.1 By Clinical Phase
    • 5.1.2 By Indication
    • 5.1.3 By Drug
    • 5.1.4 By Type of Linker
    • 5.1.5 By Mode of Action
    • 5.1.6 By Technology
  • 5.2 By Research Organizations
    • 5.2.1 By Phase
    • 5.2.2 By Indication
    • 5.2.3 By Drug
    • 5.2.4 By Type of Linker
    • 5.2.5 By Mode of Action

6. Drivers and Challenges

  • 6.1 Drivers
    • 6.1.1 Rising Global Cancer Epidemics
    • 6.1.2 Advances in Linking Technologies Re-Instills Hope in ADC
    • 6.1.3 Efforts towards Patent Protection to Drive ADC Market
    • 6.1.4 Increasing Demand for Antibody Drug Conjugates
  • 6.2 Challenges
    • 6.2.1 Production Hurdles and Cost
    • 6.2.2 Inadequacy of Experienced Manufacturers
    • 6.2.3 Regulatory Challenges

7. Major Potential ADCs in Pipeline

  • 7.1 By Companies
    • 7.1.1 Glembatumumab Vedotin Therapeutics /CDX-011 - Celldex
    • 7.1.2 Coltuximab Ravtansine/SAR3419 - ImmunoGen Inc.
    • 7.1.3 Indatuximab Ravtansine/BT-062 - Biotest
    • 7.1.4 Anti-PSMA ADC Therapeutic - Progenics Pharmaceuticals
    • 7.1.5 Polatuzumab Vedotin/RG7596 - Roche Genentech
    • 7.1.6 DMUC-4064A/RG7882 - Roche Genentech
    • 7.1.7 Mirvetuximab Soravtansine/IMGN853 - ImmunoGen Inc.
    • 7.1.8 Anti-guanylyl Cyclase C/Anti-GCC ADC - Takeda Millennium
  • 7.2 By Research
    • 7.2.1 SGM-101 - SurgiMab in Collaboration with Center for Human Drug Research, Netherlands
    • 7.2.2 Panitumumab-IRDye800 - Eben Rosenthal/Stanford University
    • 7.2.3 90Yttrium Ibritumomab Tiuxetan (Zevalin) - Biogen Idec in Collaboration with Soroka University Medical Center
    • 7.2.4 MOC31-PE - Creative Biolabs in Collaboration with Oslo University Hospital

8. Trends and Developments

  • 8.1 ADC at the Forefront of Treating Hematological Malignancies
  • 8.2 ADCs Proving Advantageous for Breast Cancer Patients

9. Strategic Collaborations in the ADC Industry

10. Competitive Assessment

  • 10.1 Seattle Genetics, Inc.
  • 10.2 F. Hoffman-La Roche Ltd.
  • 10.3 ImmunoGen, Inc.
  • 10.4 Bayer AG
  • 10.5 Novartis AG
  • 10.6 Takeda Pharmaceutical Company Limited
  • 10.7 Immunomedics, Inc.
  • 10.8 Agensys, Inc.
  • 10.9 Concortis Biotherapeutics
  • 10.10 NBE-Therapeutics

List of Figures:

  • Figure 3-1: ADC - Mechanism of Action
  • Figure 4-1: Global - ADC Market (Billion US$), 2015-2022
  • Figure 4-2: Global - ADCETRIS Market (Billion US$), 2015-2022
  • Figure 4-3: Global - Kadcyla Market (Billion US$), 2015-2022
  • Figure 5-1: Global - ADCs Pipeline by Developing Organizations (%), 2016
  • Figure 5-2: Global - ADC Pipeline of Companies by Clinical Phase (%), 2016
  • Figure 5-3: Global - ADC Pipeline of Companies by Indication (%), 2016
  • Figure 5-4: Global - ADC Pipeline of Companies by Drug (%), 2016
  • Figure 5-5: Global - ADC Pipeline of Companies by Type of Linker (%), 2016
  • Figure 5-6: Global - ADC Pipeline of Companies by Mode of Action (%), 2016
  • Figure 5-7: Global - ADC Pipeline of Companies by Technology (%), 2016
  • Figure 5-8: Global - ADC Pipeline of Research Organization by Clinical Phase (%), 2016
  • Figure 5-9: Global - ADC Pipeline of Research Organization by Indication (%), 2016
  • Figure 5-10: Global - ADC Pipeline of Research Organization by Drug (%), 2016
  • Figure 5-11: Global - ADC Pipeline of Research Organization by Type of Linker (%), 2016
  • Figure 5-12: Global - ADC Pipeline of Research Organization by Mode of Action (%), 2016
  • Figure 10-1: Novartis AG - Net Sales Breakup by Business Segments (%), 2016
  • Figure 10-2: Novartis AG - Net Sales Breakup by Geography (%), 2016
  • Figure 10-3: Takeda Pharmaceutical Company Limited - Ethical Drugs Revenue Breakup by Geography (%), 2016
  • Figure 10-4: Immunomedics, Inc. - Revenue Breakup by Geography (%), 2016
  • Figure 10-5: Astellas Pharma Inc. - Sales Breakup by Business Segments (%), 2016
  • Figure 10-6: Astellas Pharma Inc. - Sales Breakup by Geography (%), 2016

List of Tables:

  • Table 4-1: Potential Patients for ADCETRIS (2012)
  • Table 4-2: Ongoing Trials for ADCETRIS
  • Table 4-3: Potential Patients for Kadcyla (2012)
  • Table 4-4: Ongoing Trials for Kadcyla
  • Table 5-1: Global - ADC Pipeline of Companies
  • Table 5-2: Global - ADC Pipeline of Research Organization
  • Table 9-1: Strategic Collaborations in the ADC Industry (2014-2016)
  • Table 10-1: Top Companies by ADCs in Pipeline (2016)
  • Table 10-2: Seattle Genetics, Inc. - ADCs in Pipeline
  • Table 10-3: Seattle Genetics, Inc. - Key Financials (Million US$), 2013-2015
  • Table 10-4: Seattle Genetics, Inc. - Strengths and Weaknesses
  • Table 10-5: F. Hoffman-La Roche Ltd. - ADCs in Pipeline
  • Table 10-6: F. Hoffman-La Roche Ltd. - Key Financials (Million US$), 2013-2015
  • Table 10-7: F. Hoffman-La Roche Ltd. - Strengths and Weaknesses
  • Table 10-8: ImmunoGen, Inc. - ADCs in Pipeline
  • Table 10-9: ImmunoGen, Inc. - Key Financials (Million US$), 2014-2016
  • Table 10-10: ImmunoGen, Inc. - Strengths and Weaknesses
  • Table 10-11: Bayer AG - ADCs in Pipeline
  • Table 10-12: Bayer AG - Key Financials (Million US$), 2013-2015
  • Table 10-13: Bayer AG - Strengths and Weaknesses
  • Table 10-14: Novartis AG - ADCs in Pipeline
  • Table 10-15: Novartis AG - Key Financials (Million US$), 2014-2016
  • Table 10-16: Novartis International AG - Strengths and Weaknesses
  • Table 10-17: Takeda Pharmaceutical Company Limited - ADCs in Pipeline
  • Table 10-18: Millenium Pharmaceuticals - ADCs in Pipeline
  • Table 10-19: Takeda Pharmaceutical Company Limited - Key Financials (Million US$), 2014-2016
  • Table 10-20: Immunomedics, Inc. - ADCs in Pipeline
  • Table 10-21: Immunomedics, Inc. - Key Financials (Million US$), 2014-2016
  • Table 10-22: Agensys, Inc. - ADCs in Pipeline
  • Table 10-23: Astellas Pharma Inc. - Key Financials (Million US$), 2014-2016
  • Table 10-24: Oxford BioTherapeutics - ADCs in Pipeline
  • Table 10-25: Concortis Biotherapeutics - ADCs in Pipeline
  • Table 10-26: NBE-Therapeutics - ADCs in Pipeline
Back to Top